develop invasive fungal infections. [1] [2] [3] [4] The diagnosis of fungal infections is particularly difficult in immunocompromised patients, and most patients are treated presumptively. Sixty-four adult patients (median age 43) with hematologic malignancies who were immunocompromised after Early institution of anti-fungal therapy is associated with better outcome, and withholding therapy until a definitive allogeneic (n = 23) or autologous (n = 9) blood/marrow transplantation, or chemotherapy (n = 32) received 68 diagnosis is made results in dissemination of the infection with a high mortality.
was 66%. Five of seven evaluable patients with aspergillus pneumonia responded. Response rates were compa-A number of lipid-based formulations of amphotericin have been developed to improve the tissue distribution of rable for chemotherapy, autograft and allograft recipients. The change in serum creatinine from the beginning amphotericin and to reduce the toxicity associated with conventional amphotericin. 10 Amphotericin B lipid comto the end of therapy was −284 to +277 mol/l (median +24). The creatinine doubled during seven evaluable plex (ABLC) is derived from a liposomal formulation of amphotericin B consisting of dimyristoyl-phosphatidylcourses of therapy, five of which were associated with concomitant nephrotoxic therapy. Nephrotoxicity was choline and dimyristoyl-phosphatidylglycerol in a 7:3 molar ratio. Unlike the original liposomal formulation, comparable for transplant and chemotherapy patients. Renal dysfunction necessitated discontinuation of ABLC has a ribbon-like appearance. 10 Here, we report our experience with the use of ABLC ABLC in only four patients. These data suggest that ABLC is effective in presumed or confirmed fungal for the treatment of suspected or proven fungal sepsis in immunocompromised patients with hematologic maliginfections in immunocompromised patients after transplantation or chemotherapy.
nancies undergoing BMT or receiving chemotherapy. Keywords: Abelcet; amphotericin B, amphotericin B lipid complex; aspergillosis; candidiasis; fungal infection
Patients and methods

Approximately one-third of neutropenic patients who
Between May 1994 and October 1995, 64 adult patients remain persistently febrile on standard antibiotic therapy with hematologic malignancies who were immunocompromised or neutropenic as a result of chemotherapy or BMT received ABLC (Abelcet, The Liposome Company, Prince-
Diagnosis of fungal infections
ABLC (usually from the morning of the day ABLC was started) was considered the baseline creatinine, and the first Refractory fever not responding to at least 72 h of broadcreatinine level after the last dose of ABLC (usually from spectrum combination antibiotic therapy and/or coarse pulthe morning of the day after ABLC was stopped) was conmonary infiltrates with negative cultures from all approprisidered the final creatinine. The effect of the drug on the ate sites were considered evidence of a presumptive fungal kidneys was expressed as the difference in these two infection. Patients with coarse pulmonary infiltrates usually values. Concomitant therapy with other nephrotoxic drugs received therapy directed against atypical bacteria, Pneu-(cyclosporine, ganciclovir, foscarnet, high-dose intravenous mocystis carinii, and cytomegalovirus in varying combiacyclovir, vancomycin and aminoglycosides) was specifinations depending upon the clinical situation in addition to cally recorded. anti-fungal therapy.
Data were collected using a standard proforma at the Confirmed fungal infections were diagnosed on the basis time of treatment or retrospectively from the notes (Royal of positive cultures or histologic results. Growth of a CanLondon Hospital and Royal Liverpool University Hospital) dida species organism from stool or throat in the absence of and the prospective Leukaemia/Myeloma Research Datasymptoms was not considered an evidence of candidiasis.
bases of the Royal Marsden Hospital.
12,13
ABLC therapy Results The indications for ABLC therapy 11 were as follows: (1) proven invasive fungal infection; (2) strong clinicoradi- Table 1 shows the baseline characteristics of the 64 ologic picture of fungal infection in patients who were neupatients. A total of 68 treatment courses was administered tropenic and expected to remain neutropenic for the next (four patients received two treatment courses each). The few days, and who were on other nephrotoxic drugs; dose was 5 mg/kg during 67 courses, and 3 mg/kg during (3) refractory fever with compromised renal function one. The drug was administered daily during 63 courses, (у50% elevation of creatinine from baseline) and/or high and daily followed by every alternate day during five. intravenous potassium supplementation requirements Sixteen of the treatment courses were for microbiologi-(у120 mEq per day); (4) failure to respond to conventional cally confirmed fungal infections (six in BMT recipients), amphotericin or fluconazole (persistent fever for 3 days and 52 for presumptive infections (28 in BMT recipients). after introduction of antifungal therapy in presumed infecTen of the confirmed infections were due to Aspergillus tions, or failure to show any clinical, radiologic or spp. (microscopic/culture examination of sputum, bronmicrobiologic sign of improvement for 3 days in confirmed choalveolar lavage or sinus drainage), five due to Candida infections); or (5) intolerance of conventional amphotericin spp., and one due to Cryptococcus neoformans ( Table 2 ). (severe systemic reactions despite adequate premedication).
Hepatosplenic candidiasis was diagnosed in one patient on ABLC was administered intravenously at a daily dose of the basis of fever, neutrophilia, liver function abnormalities, 5 mg/kg. Premedication with corticosteroids or antihistaand a characteristic appearance of the liver and the spleen mine agents was not usually employed. Treatment courses on ultrasonography. However, a liver biopsy was not percomprising at least four doses of ABLC were considered formed. This patient has been included in the presumptive evaluable for efficacy as well as toxicity. Treatment courses infections group. comprising less than four doses of ABLC were not con-
The indications for anti-fungal therapy in patients withsidered evaluable for efficacy, but were evaluated for nephrotoxicity and systemic adverse reactions. All patients were monitored with daily serum creatinine measurements. The last creatinine level prior to starting 41 Table 2 Confirmed fungal infections and response pneumonia. However, on retrospective review, the creatinine was found to have decreased after an initial rise while of the lung infiltrates on CT scanning occurred over the ensuing several weeks with intraconazole maintenance.
One patient with the characteristic clinical and radiologic picture of hepaAnother patient with pulmonary aspergillosis in whom 7
tosplenic candidiasis but in whom microbiologic documentation was not available has been included in the presumptive therapy group. The syndays of ABLC resulted in over 50% clearance of lung infildrome resolved completely on ABLC (see text).
trates and resolution of all clinical symptoms was classified a Two patients were switched to prolonged oral itraconazole when all clinias a partial responder because nephrotoxicity necessitated cal symptoms had resolved, repeat sputum cultures were negative, and the discontinuation of ABLC.
radiologic changes had improved by 90-95%.
Four patients did not respond, and the overall response rate was 71% (10 of 14). Three of the four non-responders died as a result of the fungal infection, and one died out confirmed fungal infections were: refractory fever because of complications of the underlying disease. Four (n = 17), pulmonary infiltrates (n = 16), combination of the of six transplant recipients, including three of four with two (n = 17), oral mucositis (n = 1), and a characteristic cliAspergillus pneumonia responded. nicoradiologic picture of hepatosplenic candidiasis (n = 1). Table 2 shows response by site of infection and species. The indications for the use of ABLC (rather than convenAll five patients with candidiasis responded, while the tional amphotericin or fluconazole/itraconazole) are shown response rate in pulmonary aspergillosis was 71% (five of in Table 3. seven). None of the evaluable patients with aspergillosis Fifty-three courses comprising at least four doses (4-58 had received conventional amphotericin prior to receiving doses, median 10) were considered evaluable for efficacy, ABLC, but all the patients with candidiasis had received whereas 15 courses of one to three doses were considered conventional amphotericin for 3-7 days prior to starting non-evaluable for efficacy. Fourteen of the evaluable ABLC. courses were for confirmed fungal infections (six in BMT Three of the seven evaluable patients with pulmonary recipients), and 39 for presumed infections (23 in BMT aspergillosis had neutrophil counts of Ͻ0.5 × 10 9 /l at the recipients).
onset of therapy; partial response was seen in one, and the drug was changed to liposomal amphotericin (AmBisome, Non-evaluable courses NexStar, Boulder, CO, USA) in the other two due to nephrotoxicity after 4 and 7 days of therapy. All four Five patients developed systemic reactions to ABLC (fever patients with neutrophil counts of у0.5 × 10 9 /l at the onset with or without rigor and sweating) on the first day, and of treatment responded. did not receive a second dose of the drug. None of these had received any premedication for ABLC administration.
Eight patients (including one with Aspergillus pneumonia)
Response in presumptive infections died as a result of the underlying malignancy or compliNineteen of the 39 empiric courses resulted in complete cations of therapy after receiving one to three doses of response (resolution of fever or pulmonary infiltrates, or ABLC. The drug was discontinued after two doses in a complete resolution of the clinicoradiologic picture of hepapatient who was being treated empirically and whose gentosplenic candidiasis), and six in partial response eral clinical condition improved significantly. The drug was (incomplete resolution of pulmonary infiltrates). Fourteen discontinued due to an apparent elevation in serum creaticourses failed, resulting in a 63% response rate (24 of 38). nine after three doses in another patient with Aspergillus Overall response Table 3 Indication for ABLC
The overall response rate was 66% (35 of 53), and was Nephrotoxicity necessitated discontinuation of ABLC in only three patients. The creatinine increased by Ͼ50% of the baseline value in 10 of 24 allograft, two of 10 autograft, amphotericin in 178 patients with invasive aspergillosis. Of the 111 patients considered evaluable for response, 40% of and seven of 34 chemotherapy recipients (P = 0.18, 2 test). As Table 4 shows, there was a trend towards patients on the ABLC-treated patients responded compared with 23% of those treated with conventional amphotericin cyclosporine and those with initially normal creatinine to develop more elevated creatinine.
(P = 0.002). Despite the high concentrations in the liver and the lungs, concentrations in the kidneys are comparable to conventional amphotericin and plasma levels are consistently Discussion lower, 16 which may explain the kidney-sparing effect of ABLC. Our data suggest that ABLC is effective for the treatment of microbiologically proven or clinically suspected fungal
We found that although serum creatinine levels tended to increase, significant elevations (to more than double the infections in immunocompromised patients with hematologic malignancies including patients failing previous therbaseline) were seen in less than 15% of the patients, most of whom were receiving other nephrotoxic agents as well. apy with fluconazole or conventional amphotericin. It may thus provide a useful first-line or salvage alternative to conMore importantly, renal toxicity resulted in discontinuation of the drug in only four of 68 cases (6%). As Table 4 ventional amphotericin in the setting of BMT or chemotherapy. As observed by others, 14, 15 our data show that shows, no factor was consistently associated with elevation in creatinine levels. nephrotoxicity is not a major problem with ABLC.
The pharmacokinetic properties of ABLC can explain its Because of their high cost, drugs such as ABLC are usually used when the patient's clinical situation is poor, somefavorable toxicity and efficacy profile. The results of tissue distribution studies with ABLC in animals have shown a times when significant multi-organ dysfunction is present. In some of these cases, failure of therapy is due to death dose-dependent increase in mean amphotericin concentrations in the liver, spleen and lung. 16 The liver, spleen resulting from causes other than the fungal infection. It is possible that the use of ABLC earlier on, in the period of and lungs are often the sites of deep fungal infections such as candidiasis and aspergillosis. Targeted drug delivery to febrile neutropenia or after confirmed fungal infection, may allow a higher proportion of patients to be treated successthese sites could potentially be beneficial for local eradication of the infection. This could account for the high fully. We conclude that ABLC is effective for presumed or response rates in invasive fungal infections, as seen with pulmonary aspergillosis in our study. Hiemenz et al icity requiring discontinuation of ABLC is rare. The drug
